> Date Time: 2026-10-05 17:03:11 Dr Twyman clarifies differences between carotid imaging modalities, strategies to monitor aortic stenosis risk, individualized considerations for blood donation, cost/access realities for lipid-lowering therapies, reliability of wearable HRV tracking, safe heart-rate training zones, and practical grounding guidance. Audience members Scott, Terry (Speaker 1), and another participant (Speaker 4) ask questions spanning medical monitoring to lifestyle practices. ## Introduction 1. Dr Twyman: Cardiologist guiding patients through vascular imaging interpretation (carotid duplex vs CIMT), lipid and inflammation biomarkers (apoB, Lp-PLA2, oxidized phospholipids), monitoring for aortic stenosis, therapy access (PCSK9 inhibitors), exercise prescription using HRV and heart-rate zones, and evidence-informed advice on grounding and sauna use. 2. Speaker 1 (Terry): Participant asking about carotid tests, leather-soled grounding footwear, and distinguishing exercise intolerance from deconditioning; shares personal grounding and hiking experiences. 3. Speaker 3 (Scott): Participant asking about blood donation post-op, PCSK9 inhibitor timelines/costs, and practical year-round grounding strategies and measurement. 4. Speaker 4 (Unknown Speaker): Participant with brief interjections and a question about exercise intolerance. ## Key Points 1. Carotid duplex measures blood-flow velocity and grades stenosis; CIMT visually estimates plaque burden and intima thickness, indicating ongoing vascular injury. 2. CIMT plaque detection often uses a threshold >1.0 mm; lower cutpoints can identify earlier disease but may reflect inflammation rather than mature plaque. 3. For Lp(a)-associated aortic stenosis risk, echocardiograms about every three years are reasonable; lab markers (oxidized phospholipids, IL-6, Lp-PLA2 activity) help gauge inflammatory progression. 4. Blood donation should be individualized; ensure adequate hemoglobin and iron stores to avoid fatigue and reduced exercise tolerance, particularly post-surgery or with testosterone-induced erythrocytosis.

Let me know in the comments any feedback Thank you

I will be discussing my take on the recently announced failure of Pelacarsen to lower cardiac events in patients with elevated Lp(a) If you are unable to attend LIVE and want to ask a question, then please leave the question in the comments of this posts and I will answer it We will see how a hybrid of asynchronous questions with Live questions work to increase the volume of questions and educational opportunities for this group's members